

Alteration to the specific conditions relating to cholesterol-reducing medication

Presented to the Minister of VWS on 14 april 2008

Summary

Based on the enormous difference in the cost-effectiveness of simvastatin compared to other cholesterol-reducing medication, CVZ has advised the Minister to reimburse treatment with other cholesterol-reducing medication only when treatment with simvastatin is insufficiently effective or if simvastatin cannot be used for medical reasons. CVZ also advises adjusting the Health Insurance Regulation such that the Minister is given the authority to indicate a preference for one or more medicines within a group of interchangeable medicines. This advice will lead to a total cost reduction of approximately 169 to 226 million euros per year, whilst the quality of treatment remains the same.